Professor Claude M. Wischik, co-founder and Executive Chairman of TauRx Therapeutics, along with colleagues at the University of Aberdeen, has devoted nearly 30 years to investigating the structure and role of tau tangles in the development of Alzheimer’s, frontotemporal dementia and other neurodegenerative diseases. Prof. Wischik discovered that the neurofibrillary tangles seen in Alzheimer’s disease are made of sub-units of the tau protein and he and his team have published extensively in the field.

Al-Hilaly, Y.K. et al. (2018) Cysteine-independent inhibition of Alzheimer’s disease-like paired helical filament assembly by leuco-methylthioninium (LMT) J. Molec. Biol., Available at: Journal of Molecular Biology

Frahm, S, et al. (2018) Alpha-Synuclein transgenic mice, h-α-SynL62, display α-Syn aggregation and a dopaminergic phenotype reminiscent of Parkinson's disease. Available at: Behavioural Brain Research.

König, M., et al (2018) Increased cholinergic response in α-synuclein transgenic mice (h-α-synL62). Available at: ACS Chemical Neuroscience

Schwab, K, et al. (2018) A Protein Aggregation Inhibitor, Leuco-Methylthioninium Bis(Hydromethanesulfonate), Decreases α-Synuclein Inclusions in a Transgenic Mouse Model of Synucleinopathy. Available at: Frontiers in Molecular Neuroscience

Wilcock, G.K., et al (2018) Correspondence: Letter by Howard and Berry and Response by Wilcock et al. Is LMTM the Norwegian Blue of Alzheimer's Therapy? Available at: Journal of Alzheimer's Disease.